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The serotonin (5-hydroxytryptamine) 2A receptor (5-
HT2A) is an important G protein-coupled receptor
(GPCR) that mediates the effects of hallucinogens and is
the target of a number of commonly prescribed medica-
tions including atypical antipsychotics, antidepres-
sants, and anxiolytics. The 5-HT2A receptor possesses a
canonical Type I PDZ-binding domain (X-Ser/Thr-X-)
at the carboxyl terminus and has been predicted, but
never demonstrated, to interact with PDZ domain-con-
taining proteins. We discovered that PSD-95, a proto-
typic PDZ domain-containing protein, directly associ-
ates with the 5-HT2A receptor and regulates 5-HT2A
receptor-mediated signaling and trafficking in HEK-293
cells. Co-immunoprecipitation studies revealed that the
native 5-HT2A receptor, but not a mutant lacking the
PDZ-binding domain, interacted directly with PSD-95.
The association with PSD-95 enhanced 5-HT2A receptor-
mediated signal transduction, a novel action of PSD-95
on GPCRs. The augmentation of 5-HT2A receptor signal-
ing by PSD-95 was not accompanied by alteration in the
kinetics of 5-HT2A receptor desensitization but was as-
sociated with the inhibition of agonist-induced 5-HT2A
receptor internalization. Additional studies demon-
strated that 5-HT2A receptor and PSD-95 were co-local-
ized in clusters on the cell surface of HEK-293 cells.
Taken together, the present work elucidates novel roles
for PSD-95 in regulating the functional activity and in-
tracellular trafficking of 5-HT2A receptors and possibly
other GPCRs.
The serotonin (5-hydroxytryptamine) 2A receptor (5-HT2A)
1
mediates the effects of many (1) but not all hallucinogens (2, 3)
and is the target of a number of commonly prescribed thera-
peutic agents including atypical antipsychotics, antidepres-
sants, and anxiolytics (4, 5). As with other G protein-coupled
receptors (GPCRs) (6–8), elucidating the regulatory mecha-
nisms for 5-HT2A receptor signaling and trafficking provides
important insights into the therapeutic mechanisms of drugs
that target the 5-HT2A receptor and has implications for the
rational design of novel medications (5, 6).
The 5-HT2A receptor, the most abundant serotonin receptor
in the cerebral cortex, is enriched in dendritic shafts and, to a
lesser extent, asymmetric synapses and dendritic spines of
pyramidal neurons primarily from Layers IV and V (9–13). The
last four amino acids (VSCV) of the carboxyl terminus of the
5-HT2A receptor constitute a canonical Type I PDZ-binding
domain (X-Ser/Thr-X-) (14). The PDZ-binding domain is lo-
cated at the carboxyl terminus of a variety of proteins including
many GPCRs and is known to associate with PSD-95/Discs-
large/ZO-1 (PDZ) domain-containing proteins of which postsyn-
aptic density 95 (PSD-95, also known as synapse-associated
protein 90 or SAP-90, is a prototypic member (15, 16). These
multi-domain molecules not only target and provide scaffolds
for protein-protein interactions but can also modulate the func-
tions of ion channels and receptors with which they associate
(16–20). The disruption of the association between PDZ pro-
teins and their targets contributes to the pathogenesis of a
number of human diseases (16, 21, 22), most probably because
of the failure of PDZ proteins to appropriately target and mod-
ulate the actions of the associated proteins.
Na/H exchanger regulatory factor (NHE-RF) was the first
PDZ domain-containing protein that was reported to modulate
the function of a GPCR (e.g. the 2-adrenergic receptor (2-AR))
(23). Subsequently, PSD-95 was found to associate with and
inhibit the internalization of 1-ARs and to facilitate the inter-
action between the 1-AR and the N-methyl-D-aspartate iono-
tropic glutamate receptor (24, 25). Among the 5-HT2 class of
serotonin receptors, a multi-PDZ domain-containing protein,
MUPP1, associates with 5-HT2C receptors in vitro and in vivo
(26). MUPP1 has also been predicted to interact with both the
5-HT2A and the 5-HT2B receptor based on its ability to bind to
purified COOH-terminal fusion proteins of both receptors in
vitro (26). Furthermore, a proteomic approach has recently
identified PSD-95 as a component of a multi-protein complex
that associates with the 5-HT2C receptor in vivo (27). PSD-95,
similar to the 5-HT2A receptor, is enriched in asymmetric syn-
apses and dendritic spines of cortical pyramidal neurons (28,
29) and is thus predicted to interact with 5-HT2A receptors. The
functional significance of any association between PDZ pro-
teins and 5-HT receptors is unknown because none has been
previously reported.
Therefore, we set out to investigate whether PSD-95 inter-
acts with and regulates 5-HT2A receptors. A combination of
biochemical and immunocytochemical approaches demon-
strated that PSD-95 directly interacts with the 5-HT2A receptor
in vitro. We also discovered that PSD-95 enhanced 5-HT2A
receptor-mediated signaling, inhibited agonist-induced 5-HT2A
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receptor internalization, and promoted 5-HT2A receptor clus-
tering on the plasma membrane. Thus, this work demonstrates
a novel role for PSD-95 in modulating the activity of a GPCR.
These findings have important implications for elucidating the
roles of PDZ domain-containing proteins in regulating the func-
tions of the 5-HT family of receptors and possibly other GPCRs.
EXPERIMENTAL PROCEDURES
cDNA Constructs and Reagents—The construct coding for FLAG-
tagged wild type (WT) rat 5-HT2A receptor (FLAG-5-HT2A) was modi-
fied from a similar construct that has been described previously (30) by
adding an amino-terminal cleavable signal peptide sequence [MKTI-
IALSYIFCLVFA (31)] derived from influenza hemagglutinin. The ad-
dition of such a signal sequence has been shown to increase the expres-
sion of GPCRs (31). FLAG-5-HT2A469–471 was constructed by using
FLAG-5-HT2A as the template and by introducing a premature stop
codon at residue 469, the third to the last amino acid of the carboxyl
terminus, using site-directed mutagenesis (5-primer: 5-CGTGAAT-
GAAAAGGTTTGATGTGTGTGATCTAGAGGGCCC-3, and 3-primer:
5-GGGCCCTCTAGATCACACACATCAAACCTTTTCATTCACG)-3
(QuikChange). Deletion of amino acid residues 469–471 effectively
ablates the PDZ-binding domain of the 5-HT2A receptor. PSD-95-GFP (a
generous gift from D. Bredt) has been described elsewhere (32). The
EGFP-C2 vector (Clontech, Palo Alto, CA) contained the GFP coding
sequence. The constitutively active Gq mutant (Q229L) (a generous
gift from D. Siderovski) has been described elsewhere (33). All of the
constructs containing inserts in the appropriate orientation were veri-
fied by automated sequencing (Cleveland Genomics, Cleveland, OH).
5-Hydroxytryptamine creatinine sulfate (5-HT), quipazine, cloza-
pine, chlorpromazine, ()-2,5-dimethoxy-4-iodoamphetamine hydro-
chloride, CHAPS, and sodium orthovanadate were acquired from
Sigma. [3H]Ketanserin and myo-[3H]inositol were purchased from
PerkinElmer Life Sciences.
Transfection of HEK-293 Cells—Human embryonic kidney 293
(HEK-293) cells were maintained in Dulbecco’s modified Eagle’s me-
dium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1 mM
sodium pyruvate, penicillin (100 units/ml), and streptomycin (100 mg/
ml) (Invitrogen) at 37 °C and 5% CO2. Transient transfection with
FuGENE 6 (Roche Applied Sciences) using a FuGENE 6 to DNA ratio
of 5:1 was performed according to the manufacturer’s recommenda-
tions. A total of 6 g of DNA was used in each co-transfection, 4 g of
which were vector, 5-HT2A receptor, or mutant 5-HT2A receptor DNA
and 2 g of which were DNA encoding either PSD-95-GFP or GFP.
Co-immunoprecipitation and Immunoblot—At 24 h after co-transfec-
tion, HEK-293 cells were split into 6-well plates and cultured first in
DMEM supplemented with 5% dialyzed FBS for 24 h and then in
DMEM without serum for an additional 24 h. Cells were washed at 4 °C
twice with PBS and once with Buffer A (50 mM HEPES, 150 mM NaCl,
1 mM EDTA, 10 mM Na4P2O7, and 2 mM sodium orthovanadate, pH 7.5).
Cells were lysed by incubation on a rocker platform at 4 °C for 15 min
in Buffer A containing 1.5% CHAPS and EDTA-free Complete protease
inhibitor tablets (Roche Applied Sciences). A portion of the cell lysates
was saved for subsequent determination of total protein expression
levels, and the remainder was incubated with Sepharose beads conju-
gated to a monoclonal FLAG antibody (Sigma) at 4 °C for 2 h. The beads
were washed at 4 °C for three times in Buffer B (50 mM HEPES, 150 mM
NaCl, 0.3% Triton X-100, and 10% glycerol, pH 7.5). Immunoprecipi-
tated proteins were then eluted from the beads by resuspension in 2
SDS sample buffer. Samples were heated for 5 min at 67 °C, and
proteins were resolved by SDS-PAGE and transferred to nitrocellulose
membranes. Immunoblotting was performed according to standard
FIG. 1. PSD-95 interacts with native 5-HT2A receptors but not
with mutant 5-HT2A receptors lacking the PDZ binding motif.
For these experiments, HEK-293 cells were either nontransfected
(lanes 1 and 2) or transiently co-transfected with FLAG-5-HT2A  GFP
(lanes 3 and 4), FLAG-5-HT2A469–471  GFP (lanes 5 and 6),
pcDNA3  PSD95-GFP (lanes 7 and 8), FLAG-5-HT2A  PSD95-GFP
(lanes 9 and 10), or FLAG-5-HT2A469–471  PSD95-GFP (lanes 11
and 12). FLAG-tagged native or mutant 5-HT2A receptors were immu-
noprecipitated by a monoclonal FLAG antibody conjugated to Sepha-
rose beads. PSD95-GFP or GFP was detected by a polyclonal GFP
antibody, and FLAG-5-HT2A or FLAG-5-HT2A469–471 was detected
by a polyclonal FLAG antibody on Western blots. The 5-HT2A receptor
and PSD-95 appear as 62- and 95-kDa proteins, respectively. Repre-
sentative immunoblots from a single experiment that has been repli-
cated three times with equivalent results are shown. A–B, immunoblots
from immunoprecipitates. C–D, immunoblots from cell lysates. E, quan-
tification of PSD-95 levels on immunoblots from three independent
experiments. The average levels of PSD-95 in immunoprecipitates from
cells co-expressing vector, FLAG-5-HT2A, or FLAG-5-HT2A469–471 
PSD-95-GFP were normalized to the corresponding levels in cell ly-
sates. IB, immunoblotting.
FIG. 2. PSD-95 enhances 5-HT2A receptor-mediated signal
transduction. For these experiments, HEK-293 cells were transiently
co-transfected with FLAG-5-HT2A  GFP (f), FLAG-5-HT2A469–471
 GFP (Œ), FLAG-5-HT2A  PSD-95-GFP (), or FLAG-5-HT2A469–
471  PSD-95-GFP (‚). Dose-response PI hydrolysis and saturation
binding assays were performed on cells from the same batch of trans-
fection with efficacies (Emax values) determined from PI hydrolysis
normalized to receptor expression (Bmax values in fmol/mg; see “Exper-
imental Procedures”). The average results (S.E.) from three independ-
ent experiments are shown. EC50 and relative Emax values are shown
in Table I.
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methods (30, 34). A polyclonal GFP antibody (1:2000) (Abcam,
Cambridge, United Kingdom) was used to detect PSD-95-GFP or GFP.
A rabbit polyclonal FLAG antibody (1:1500) was used to detect FLAG-
tagged WT and mutant 5-HT2A receptors. The constitutively active Gq
mutant and the endogenous WT Gq in cell lysates were detected by a
rabbit polyclonal Gq antibody (1:2000) (Santa Cruz Biotechnology,
Santa Cruz, CA). The levels of PSD-95-GFP expression from immuno-
precipitates and cell lysates were quantified using a chemiluminescence
imaging system (Kodak Scientific Imaging System, Eastman Kodak
Co.). The levels of PSD-95-GFP expression from immunoprecipitates
were subsequently normalized to corresponding levels in cell lysates.
Agonist-mediated Internalization—At 24 h after co-transfection,
HEK-293 cells were split into 24-well plates containing poly-L-lysine-
coated coverslips and maintained in DMEM supplemented with 5%
dialyzed FBS for 24 h and then in DMEM without serum for an addi-
tional 24 h. Cells were treated for 15 min at 37 °C with 5-HT at a final
concentration of 10 M. Treatment was terminated by placing cells at
4 °C, removing media, and fixing with 4% paraformaldehyde. Immuno-
cytochemistry was performed, confocal images were acquired (see “Im-
munocytochemistry, Confocal Microscopy, and Image Quantification”),
and internalization was quantified using the MetaView imaging soft-
ware (Universal Imaging, Downingtown, PA).
Phosphoinositide Hydrolysis, Radioligand Binding, and Desensitiza-
tion Assays—Phosphoinositide (PI) hydrolysis and saturation radioli-
gand binding assays were performed on cells from the same transfec-
tion. At 24 h following transfection, HEK-293 cells were either 1) split
into poly-L-lysine-coated 24-well plates and maintained in DMEM sup-
plemented with 5% dialyzed FBS for 24 h and then in serum-free and
inositol-free DMEM for an additional 24 h before performing PI hydrol-
ysis assay or 2) kept in DMEM supplemented with 5% dialyzed FBS for
24 h and then in serum-free DMEM for additional 24 h before harvest-
ing cell membranes for binding assay. As described previously, agonist
efficacy (Emax) and potency (EC50) were determined from dose-response
PI hydrolysis assays and kinetic binding parameters (Bmax and Kd) were
determined from saturation binding assays with [3H]ketanserin (35).
The resulting Emax values were then normalized to Bmax values with
results replicated in at least three separate experiments. PI hydrolysis
data were analyzed by nonlinear regression using the GraphPad Prism
software (San Diego, CA), and saturation binding data were analyzed
using GraphPad Prism or the weighted nonlinear least-squares curve-
fitting program LIGAND (36). Agonist-dependent desensitization of
5-HT2A receptor-mediated accumulation of inositol phosphate (IP) was
performed as described previously (34, 35).
Immunocytochemistry, Confocal Microscopy, and Image Quantifica-
tion—Dual-labeling immunocytochemistry was performed essentially
as described previously (30). HEK-293 cells were fixed with 4%
paraformaldehyde, permeabilized with 0.3% Triton X-100 at 4 °C,
blocked with 5% milk, incubated with primary antibodies overnight at
4 °C and then with secondary antibodies, conjugated to the appropriate
Alexa Fluor dyes (Molecular Probes, Eugene, OR), and finally mounted
on glass slides. FLAG-tagged constructs were visualized using a mono-
clonal FLAG antibody (1:1500) (Stratagene). GFP-tagged constructs
were visualized with a rabbit polyclonal GFP antibody (1:2000) (Abcam,
Cambridge, United Kingdom). Images of cells were acquired digitally
using a Zeiss 410 confocal microscope (Oberkochen, Germany) without
saturation of pixel intensities and were subsequently analyzed using
MetaView (Universal Imaging) as previously detailed (30, 34, 35, 37,
38). For each cell in which 5-HT2A receptor internalization was quan-
tified, two measurements were made: 1) total cellular immunofluores-
cence and 2) intracellular immunofluorescence. The extent of 5-HT2A
receptor internalization was then defined as the percentage of the total
5-HT2A receptor immunofluorescence, which was intracellular. For each
sample group, at least 50 cells were quantified in a blinded fashion. In
prior studies (30, 37), we have demonstrated that this method provides
quantitative estimates of internalization that are essentially equivalent to
results obtained by biochemical techniques such as surface biotinylation.
Statistical Analysis—Data from co-immunoprecipitation and inter-
nalization studies were analyzed using the unpaired Student’s t test
TABLE I
PSD-95 potentiates 5-HT2A receptor signaling
Agonist potency (EC50) and relative agonist efficacy (normalized Emax) were determined from phosphoinositide hydrolysis assays as described
under “Experimental Procedures.” The results represent the average of three independent experiments with Emax values normalized for receptor





relative Emax  S.E.
FLAG-5-HT2A  GFP 18.1 nM (1.26  0.07) 1.00  0.02
FLAG-5-HT2A 469-471  GFP 21.6 nM (1.33  0.15)
NS 0.92  0.05NS
FLAG-5-HT2A  PSD-95-GFP 29.4 nM (1.47  0.19)
NS 1.65  0.14*
FLAG-5-HT2A 469-471  PSD-95-GFP 26.6 nM (1.42  0.16)
NS 1.07  0.07NS
FIG. 3. PSD-95 does not augment Gq signaling independent of the 5-HT2A receptor. For these experiments, a constitutively active form
of Gq (Q229L or Gq
*) was co-transfected with either GFP or PSD-95-GFP. A, representative immunoblot of total Gq from all of the sample groups
(in duplicate). B, quantification of the net pixel intensities of bands from three independent experiments showed equal levels of total Gq expression
in the presence or absence of PSD-95, both of which were significantly higher than that from nontransfected cells because of the overexpression
of Gq
*. C, PSD-95 (PSD-95  Gq
*) did not elevate Gq
*-stimulated IP accumulation over the base line (PSD-95  GFP) in the absence of 5-HT2A
receptors. Results shown represent the mean (S.E.) of three independent experiments.
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with statistical significance defined as p  0.05. Statistical significance
of the PI hydrolysis data was analyzed by GraphPad Prism using the
two-tailed paired Student’s t test and was defined as p  0.05.
RESULTS
5-HT2A Receptors Directly Interact with PSD-95 via a Type I
PDZ-binding Motif—Because the 5-HT2A receptor contains a
canonical Type I PDZ-binding domain and is found in the
postsynaptic densities of cortical neurons where PSD-95 is also
enriched (12), we predicted that 5-HT2A receptors and PSD-95
might directly associate. To test this hypothesis, we performed
co-immunoprecipitation experiments in which 5-HT2A recep-
tors and PSD-95 were co-transfected in HEK-293 cells. We
probed for GFP-tagged PSD-95 following lysis of transiently
transfected HEK-293 cells and immunoprecipitation of FLAG-
tagged WT or mutant 5-HT2A receptors. Wild type FLAG-5-
HT2A receptors were co-immunoprecipitated robustly with
PSD-95-GFP (Fig. 1A, lanes 9 and 10), indicating that 5-HT2A
receptors and PSD-95 directly interact in vitro (see Fig. 1E
for quantification).
To identify the responsible binding motif(s) on the 5-HT2A
receptor, we constructed a mutant 5-HT2A receptor (5-
HT2A469–471) that lacks the PDZ-binding domain. Ablating
the PDZ-binding domain attenuated the interaction between
FLAG-5-HT2A and PSD-95-GFP to control levels (Fig. 1, A,
lanes 11 and 12 versus lanes 7 and 8, and E), demonstrating
that the PDZ-binding domain of the 5-HT2A receptor (residues
469–471, SCV) mediates the association with PSD-95.
To further establish the specificity of the interaction between
the 5-HT2A receptor and PSD-95, we performed a number of
controls. First, we showed that cells co-transfected with PSD-
95-GFP and an empty vector (Fig. 1, A, lanes 7 and 8, and E)
yielded minimal pull-down of PSD-95. Second, no PSD-95 was
immunoprecipitated from nontransfected cells (Fig. 1A, lanes 1
and 2) or from cells co-expressing 5-HT2A receptors (WT or
mutant) and GFP (Fig. 1A, lane 3–6). These findings demon-
strated the specificity of PSD-95 association with 5-HT2A re-
ceptors. Finally, the significantly higher levels of PSD-95 that
co-immunoprecipitated with WT 5-HT2A receptors (Fig. 1A,
lanes 9 and 10) resulted neither from variations in the expres-
sion of WT or mutant 5-HT2A receptors in immunoprecipitates
(Fig. 1B, lanes 3–6 and lanes 9–12) or in cell lysates (Fig. 1D,
lanes 3–6 and lanes 9–12) nor from variations in PSD-95 ex-
pression (Fig. 1C, lanes 7–12; see Fig. 1E for quantification).
Therefore, we conclude that PSD-95 specifically associates with
5-HT2A receptors by interacting with the PDZ-binding domain
of the 5-HT2A receptor.
PSD-95 Potentiates 5-HT2A Receptor-mediated Signal Trans-
duction—We next examined whether the association between
PSD-95 and the 5-HT2A receptor has functional consequences
on 5-HT2A receptor signal transduction. Because the 5-HT2A
receptor is a Gq-coupled receptor that activates phospholipase
C (PLC) (39), we measured inositol phosphate (IP) accumula-
tion resulting from 5-HT2A receptor-mediated PI hydrolysis
(Fig. 2) and determined in parallel the expression of 5-HT2A
receptors by immunoblot analysis (Fig. 1, B and D) and satu-
ration binding assays. We then normalized the functional ac-
tivity of the 5-HT2A receptor (i.e. IP accumulation) to the ex-
pression level of the 5-HT2A receptor (i.e. Bmax), thus
accounting for minor variations in 5-HT2A receptor activation
that might have resulted from variations in receptor expres-
sion. Assays were also performed under the conditions of min-
imal receptor reserve (35).
PSD-95 significantly enhanced WT 5-HT2A receptor-medi-
ated signaling when compared with the base line (i.e. 5-HT2A
receptors co-transfected with GFP) (Fig. 2, WT 5-HT2A 
PSD-95 versus WT 5-HT2A  GFP) (Table I). The augmentation
of signaling by PSD-95 was not seen when PSD-95 was co-
transfected with the 5-HT2A469–471 mutant (Fig. 2,
5-HT2A469–471  PSD-95) (Table I). Blocking the direct
physical interaction between PSD-95 and 5-HT2A receptors
thus inhibited the ability of PSD-95 to augment 5-HT2A signal-
ing. Interestingly, PSD-95 did not alter agonist potency (Table
I), and there was no apparent alteration in the constitutive
activity of any of the receptor constructs (measured as detailed
by Shapiro et al. (40); data not shown). These results indicate
that PSD-95 via a direct physical interaction with 5-HT2A
receptors augments 5-HT2A receptor-mediated signaling.
To investigate the possibility that PSD-95 augments the PLC
signaling pathway by associating with downstream effectors
(i.e. Gq and PLC), we examined whether PSD-95 increased IP
accumulation in cells expressing a constitutively active form of
Gq (Q229L and Gq
*), which activates PLC directly (33). In
the absence of 5-HT2A receptor expression, PSD-95 neither
altered the Gq
*-stimulated IP accumulation when compared
with GFP alone (Fig. 3C) nor affected the relative expression of
Gq
* (Fig. 3, A and B). These findings strongly suggest that
PSD-95 enhances intracellular signaling at the level of recep-
tor-effector coupling and not via a receptor-independent aug-
mentation of Gq signaling.
PSD-95 Does Not Affect the Agonist-dependent Desensitiza-
tion of 5-HT2A Receptors—To determine the potential cellular
mechanisms subserving the PSD-95-mediated augmentation of
5-HT2A receptor signaling, we examined whether PSD-95 al-
ters the time course of 5-HT2A receptor desensitization. We
have previously reported that exposure to agonists inhibits the
activation of the 5-HT2A receptor by the process of desensitiza-
tion whereby receptors on the cell surface no longer respond to
agonists and fail to efficiently signal downstream pathways
(41). PSD-95 did not attenuate agonist-dependent 5-HT2A re-
ceptor desensitization when compared with the base line (Fig.
4, WT 5-HT2A  PSD-95 versus WT 5-HT2A  GFP). Likewise,
disrupting the association between PSD-95 and 5-HT2A recep-
tors had no effect on agonist-dependent desensitization of
5-HT2A receptors (Fig. 4, 5-HT2A469–471  PSD-95). Hence,
PSD-95 does not enhance 5-HT2A receptor signaling by atten-
uating the desensitization of 5-HT2A receptors.
FIG. 4. PSD-95 does not affect 5-HT2A receptor desensitization
in HEK-293 cells. For these experiments, cells were transiently co-
transfected with FLAG-5-HT2A  GFP (f), FLAG-5-HT2A469–471 
GFP (Œ), FLAG-5-HT2A  PSD-95-GFP (), or FLAG-5-HT2A469–
471  PSD-95-GFP (‚). At 48 h following transfection, cells were
incubated for 24 h with serum-free media and then pretreated for 15,
30, 60, 120, and 240 min with 300 M quipazine and subsequently
stimulated with 10 M 5-HT for 1 h before PI hydrolysis assay was
performed (see “Experimental Procedures”). 5-HT2A receptor-mediated
IP accumulation at each time point was normalized to that in cells that
were not desensitized by quipazine (at 0 min). Results from three
independent experiments showed no statistically significant difference
among the sample groups.
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PSD-95 Inhibits the Agonist-induced Internalization and
Promotes the Cell Surface Clustering of 5-HT2A Receptors—We
next investigated whether PSD-95 affects the targeting and
trafficking of 5-HT2A receptors. We have previously demon-
strated that acute exposure to agonists facilitates the redistri-
bution of 5-HT2A receptors from the plasma membrane to the
intracellular pool via receptor internalization (30). As expected,
5-HT induced the rapid internalization of WT 5-HT2A receptors
(Fig. 5, A–C versus D–F; see Fig. 7 for quantification). Interest-
ingly, PSD-95 significantly inhibited the agonist-induced
5-HT2A receptor internalization (Figs. 5, G–I versus J–L, and 7)
and promoted the co-clustering (i.e. formation of puncta con-
taining both proteins) of 5-HT2A receptors with PSD-95 on the
cell surface (Figs. 5, G–I (cross-section view), and 8, A–C
(top view)).
As an essential control, we found that disrupting the PDZ-
binding domain of the 5-HT2A receptor blocked the ability of
PSD-95 to inhibit 5-HT2A receptor internalization (Figs. 6, A–C
versus D–F, and 7). Furthermore, disrupting the PDZ-binding
domain attenuated 5-HT2A receptor clustering on the cell sur-
face (Figs. 6, A–C (cross-section view), and 8, D–F (top view)).
Interestingly, whereas WT 5-HT2A receptors appeared to
co-cluster with the membrane-bound PSD-95, mutant
5-HT2A469–471 receptors did not facilitate the formation of
PSD-95-immunoreactive puncta on the cell surface (Figs. 5, G–I
versus J–L, and 6, A–C versus D–F). Taken together, these
findings suggest that PSD-95 augments 5-HT2A receptor-me-
diated signaling at least in part by inhibiting the internaliza-
tion and promoting the cell surface clustering of 5-HT2A
receptors.
DISCUSSION
The major findings of this work are that PSD-95 directly
interacts with 5-HT2A receptors in vitro, thereby augmenting
5-HT2A receptor signaling, inhibiting the agonist-dependent
internalization, and promoting the cell surface clustering of the
5-HT2A receptor. PSD-95 was recently reported to be among the
several PDZ domain-containing proteins that physically inter-
act with the closely related 5-HT2C receptor in vivo (27),
although the physiological significance of the interaction be-
tween 5-HT receptors and PDZ domain-containing proteins is
largely unknown. Although there is precedence for GPCR sig-
naling being enhanced by another PDZ domain-containing pro-
tein (23), this is the first report that PSD-95, a prototypic PDZ
FIG. 5. PSD-95 inhibits agonist-me-
diated internalization of 5-HT2A re-
ceptors. For these studies, cells were
transiently co-transfected with FLAG-5-
HT2A  GFP (A–F) or FLAG-5-HT2A 
PSD-95-GFP (G–L). At 48 h following
transfection, cells were incubated with se-
rum-free media for 24 h and then exposed
to the vehicle (A–C and G–I) or 10 M
5-HT (D–F and J–L) for 15 min followed
by dual-labeling immunofluorescent con-
focal microscopy (see “Experimental Pro-
cedures”). Representative images from
several independent experiments are
shown. GFP (A and D) or GFP-tagged
PSD-95 (G and J) are shown in the green
channel. FLAG-tagged native 5-HT2A re-
ceptors (H and K) are shown in the red
channel, and merged images are shown in
panels C, F, I, and L. Scale bars are shown
in the merged panels.
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domain-containing protein and a major synaptic protein, en-
hances the signaling of any GPCR. Taken together, these re-
sults imply that interactions with PDZ domain-containing pro-
teins may represent a generalized mechanism for modulating
GPCR-mediated signal transduction.
PSD-95 is known to associate with a variety of target pro-
teins, including the NMDA receptor (14), 1-AR (24), neuroligin
(42), cysteine-rich interactor of PDZ three (43), and citron (44).
Superficially, the association of PSD-95 with the 5-HT2A recep-
tor is reminiscent of PSD-95 interactions with the 1-AR. Most
notably, the extreme carboxyl terminus of the 1-AR (Ser-Lys-
Val) and the 5-HT2A receptor (SCV) shares the same Type I
PDZ-binding motif (X-Ser/Thr-X-) and could conceivably in-
teract with the same PDZ domain on PSD-95. Moreover,
PSD-95 inhibits the agonist-induced internalization of both the
1-AR (24) and the 5-HT2A receptor. On the other hand, we
have discovered significant differences. In particular, PSD-95
augments 5-HT2A receptor signaling but has no effect on 1-AR
signaling (24).
The precise mechanism by which PSD-95 augments 5-HT2A-
mediated signaling is unknown but is probably because of a
direct physical interaction. Thus, PSD-95 potentiates the sig-
naling of wild-type 5-HT2A receptors but not mutant 5-HT2A
receptors lacking the PDZ-binding domain. Additionally,
PSD-95 does not augment basal (constitutive) 5-HT2A receptor
signaling, alter agonist potency, perturb the kinetics of agonist-
dependent 5-HT2A receptor desensitization, or affect the ability
of a constitutively active Gq (Gq-Q229L) to activate PLC.
Taken together, these results are consistent with the notion
that PSD-95 augments receptor-effector signaling via a direct
physical interaction between 5-HT2A receptors and PSD-95.
Based on the present finding that PSD-95 augments 5-HT2A
receptor signaling, it is reasonable to speculate that PSD-95
provides scaffolding for Gq and PLC, thereby facilitating the
interaction between the 5-HT2A receptor and these down-
stream signaling molecules. Studies to test this hypothesis are
in progress.
We have also found that PSD-95 inhibits the agonist-induced
5-HT2A receptor internalization. A possible mechanism by
which PSD-95 inhibits 5-HT2A receptor internalization is that
PSD-95 recruits and anchors multiple proteins including the
5-HT2A receptor to the plasma membrane, assembling a com-
plex that in turn prevents the internalization of component
molecules. For example, PSD-95 is known to assemble 1-AR
and NMDA receptor in the same complex (24). Consistent with
reports of cell surface co-localization between MUPP1 and
5-HT2C receptor (26) and between PSD-95 and 1-AR (24),
5-HT2A receptors also co-cluster with PSD-95 as the distribu-
FIG. 6. Disrupting PSD-95 association with the 5-HT2A receptor restores the agonist-dependent internalization of 5-HT2A recep-
tors in HEK-293 cells. For these studies, cells were transiently co-transfected with FLAG-5-HT2A469–471 and PSD-95-GFP. At 48 h following
transfection, cells were incubated in serum-free medium for 24 h and then exposed to vehicle (A–C) or 10 M 5-HT (D–F) for 15 min followed by
dual-labeling immunofluorescent confocal microscopy (see “Experimental Procedures”). Representative images are shown. GFP-tagged PSD-95 (A
and D) are shown in the green channel. FLAG-tagged mutant 5-HT2A receptors that lack the PDZ-binding domain (B and E) are shown in the red
channel, and merged images are shown in panels C and F. Scale bars are shown in the merged panels.
FIG. 7. PSD-95 inhibits agonist-mediated 5-HT2A receptor in-
ternalization-quantification. Data shown represents the mean 
S.E. of the percent of internalization from at least three independent
experiments. The number of cells in which 5-HT2A receptor internal-
ization was quantified (also see “Experimental Procedures”) for each
condition is the following: FLAG-5-HT2A  GFP (vehicle: n  52; 5-HT:
n  61), FLAG-5-HT2A  PSD95-GFP (vehicle: n  89; 5-HT: n  86),
and FLAG-5-HT2A469–471  PSD95-GFP (vehicle: n  67; 5-HT:
n  69).
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tion of PSD-95 on the plasma membrane appears more diffuse
in the absence of its association with the 5-HT2A receptor. The
co-clustering between 5-HT2A receptors and PSD-95 may re-
flect the assembly of a multi-protein signaling complex on the
cell surface that does not easily internalize following agonist
exposure. The net effect in neurons would most probably be an
enhancement of 5-HT2A-mediated signaling in regions where
5-HT2A receptors and PSD-95 are co-localized.
It is worth noting that PSD-95 inhibits the internalization
of the 5-HT2A receptor but does not affect the agonist-de-
pendent desensitization, considering that these regulatory
mechanisms for GPCRs (i.e. internalization, desensitization,
and resensitization) are frequently linked. We have previ-
ously demonstrated that both the desensitization and the
resensitization of the 5-HT2A receptor are not affected by
various well characterized inhibitors of clathrin-mediated
endocytosis in HEK-293 cells (35, 41). In addition, it is un-
likely that the PDZ-binding domain is involved in agonist-de-
pendent GPCR desensitization because disruption of the
PDZ-binding domain does not prevent 5-HT2C receptors from
undergoing desensitization (45).
Another potential mechanism for PSD-95-mediated inhibi-
tion of 5-HT2A receptor internalization could involve competi-
tion for the same binding motif with regulatory molecules that
facilitate 5-HT2A receptor internalization. Studies of PSD-95/
Kir2.3 and NHE-RF/2-AR associations suggest that phospho-
rylation of the serine or threonine residue at the 	2 position of
the canonical PDZ-binding domain by G protein-coupled recep-
tor kinases (GRK) may be the regulatory mechanism with
which PSD-95 competes (23, 46–48). One such counter-regula-
tory molecule is GRK5. Upon agonist stimulation, GRK5 phos-
phorylates the serine residue of the PDZ-binding domain of
both 1-AR and 2-AR, thereby diminishing receptor associa-
tion with PDZ proteins (PSD-95 and NHE-RF, respectively)
and facilitating receptor internalization (47, 48). Neither GRK5
nor GRK2 is likely to compete with PSD-95 for binding sites on
the 5-HT2A receptor, however, since we have demonstrated
that 5-HT2A receptors are regulated by GRK2- and GRK5-
independent processes (35).
Because PSD-95 becomes membrane-bound following palmi-
toylation (49), the preferential localization of PSD-95 to the
plasma membrane makes it unlikely that PSD-95 could en-
hance 5-HT2A receptor recycling (50), a possibility that might
otherwise confound the interpretation of the present observation.
It would be interesting to examine in the future whether an
alternatively spliced isoform of PSD-95 (PSD-95) that lacks
palmitoylation sites in the amino terminus and is not membrane-
bound (51) could inhibit 5-HT2A receptor internalization.
In summary, we have discovered a novel role for PSD-95 for
regulating the activity of GPCRs. PSD-95 augments 5-HT2A
receptor-mediated signaling in a way that requires a direct
physical interaction between 5-HT2A receptors and PSD-95.
This study demonstrates that PSD-95, a component of the
neuronal protein sorting apparatus, regulates 5-HT2A recep-
tor signaling at least in part by anchoring 5-HT2A receptors
to the cell surface in clusters that are not easily internalized
by agonists and possibly by facilitating 5-HT2A receptor in-
teraction with downstream signaling molecules. Because
5-HT2A receptors are responsible for the actions of atypical
antipsychotic drugs (4, 5, 37, 52) and most (1, 5) but not all (2,
3) hallucinogens, elucidating the cellular machinery respon-
sible for targeting and regulating 5-HT2A receptors will en-
hance our understanding of how diverse classes of drugs
exert their profound effects on human perception, emotion,
and cognition.
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FIG. 8. PSD-95 co-localizes with 5-HT2A receptors on the cell surface. For these studies, cells were transiently co-transfected with
FLAG-5-HT2A  PSD95-GFP (A–C) or FLAG-5-HT2A469–471  PSD95-GFP (D–F). At 48 h following transfection, cells were incubated with
serum-free media for 24 h and dual-labeling immunofluorescent confocal microscopy was subsequently performed (see “Experimental Procedures”).
Images shown here were confocal sections taken at the cell surface as previously detailed (30) and represent images from experiments that were
replicated at least three times. GFP-tagged PSD-95 is shown in the green channel (A and D), and FLAG-tagged native (B) and the PDZ-binding
domain-lacking mutant (E) 5-HT2A receptors are shown in the red channel. Merged images are shown in panels C and F. Co-localization is denoted
by orange arrows. Scale bars are shown in the panels marked merged.
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